Tempest Therapeutics (TPST) Company Report

Analyst Earnings Quarterly Reports

Earnings summaries and quarterly performance for Tempest Therapeutics.

Research analysts covering Tempest Therapeutics.

Recent press releases and 8-K filings for TPST.

Tempest Therapeutics Completes Asset Acquisition, Announces Leadership Changes, and Issues Warrants

TPST

M&A

CEO Change

Board Change

Tempest Therapeutics, Inc. completed the acquisition of CAR T-cell therapy assets from Erigen LLC and Factor Bioscience Inc. on February 3, 2026, issuing 8,268,495 shares of common stock as consideration.
Following the asset acquisition, Erigen LLC became the majority owner, holding approximately 61.3% of the outstanding common stock, with a total of 13,481,070 shares outstanding immediately after the share issuance.
The company distributed 6,784,989 warrants on February 3, 2026, each allowing the purchase of one common stock share at an exercise price of $18.48, with an expiration date of February 3, 2031.
Dr. Matthew Angel was appointed President and Chief Executive Officer and a Class I director on February 3, 2026, succeeding Stephen Brady, who resigned from these roles; additionally, Geoff Nichol resigned from the Board.

5 hours ago

Tempest Therapeutics Closes Acquisition of CAR-T Assets and Appoints New CEO

TPST

M&A

CEO Change

New Projects/Investments

Tempest Therapeutics has closed an all-stock transaction to acquire dual-targeting CAR-T programs and secure financing support from Factor Bioscience Inc..
This transaction extends the company's operational runway to mid-2027.
Matt Angel, Ph.D., has joined Tempest as President and Chief Executive Officer.
The acquired assets include TPST-2003, a clinical-stage dual-targeting CD-19/BCMA CAR-T, with a Biologics License Application (BLA) filing in China planned for 2027.

2 days ago

Tempest Therapeutics Announces Registered Direct Offering and Private Placement

TPST

Tempest Therapeutics, Inc. announced a registered direct offering of 1,172,414 shares of common stock (or equivalents) at $3.625 per share, and a concurrent private placement of short-term unregistered warrants to purchase up to 1,172,414 shares of common stock at an exercise price of $3.50 per share.
The offering, expected to close on or about November 25, 2025, is with a single healthcare-focused institutional investor.
The company anticipates receiving approximately $4.25 million in gross proceeds from the offering, with potential additional gross proceeds of approximately $4.1 million if the warrants are fully exercised, for a total potential of up to $8.35 million.
The net proceeds from this offering are intended primarily for working capital and general corporate purposes.

Nov 26, 2025, 1:55 PM

Tempest Therapeutics Announces Q3 2025 Financial Results

TPST

Earnings

New Projects/Investments

Demand Weakening

Tempest Therapeutics reported a net loss of $3.5 million, or $0.79 per share, for the third quarter ended September 30, 2025, compared to a net loss of $10.6 million, or $5.32 per share, for the same period in 2024.
The company concluded Q3 2025 with $7.5 million in cash and cash equivalents, a decrease from $30.3 million on December 31, 2024, primarily due to cash used in operating activities.
Research and development expenses significantly decreased to $0.6 million in Q3 2025 from $7.6 million in Q3 2024, mainly due to re-prioritizing efforts towards exploring strategic alternatives.
Tempest is continuing its strategic alternatives process to maximize stockholder value and anticipates the start of the TPST-1495 Phase 2 trial in collaboration with the NCI.

Nov 5, 2025, 2:04 PM

Tempest Therapeutics Reports Third Quarter 2025 Financial Results

TPST

Earnings

M&A

New Projects/Investments

Tempest Therapeutics reported a net loss of $3.5 million and net loss per share of $0.79 for the third quarter ended September 30, 2025, compared to $10.6 million and $5.32 respectively for the same period in 2024.
The company ended the quarter with $7.5 million in cash and cash equivalents, a decrease from $30.3 million on December 31, 2024, primarily due to cash used in operating activities.
Research and development expenses significantly decreased to $0.6 million for Q3 2025 from $7.6 million for Q3 2024, mainly due to re-prioritizing efforts towards exploring strategic alternatives.
Tempest is continuing its strategic alternatives process to maximize value for stockholders and anticipates the start of the TPST-1495 Phase 2 clinical trial.